The areas of controversy discussed during the meeting were: (1) surgery of the primary; (2) surgery of the axilla; (3) radiation—partial breast, post-mastectomy, nodal areas, advanced technologies; (4) pathology; (5) multigene signatures; (6) stroma—extracellular matrix and prognosis; (7) endocrine therapies—ovarian suppression, tamoxifen, aromatase inhibitors; (8) chemotherapies—luminal A, duration, regimen; (9) anti-HER2 therapies—combination, duration; (10) neo-adjuvant systemic therapy; (11) bisphosphonates—anti-tumour effects; and (12) follow-up after early breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.